Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–30 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Gestational Diabetes Mellitus
Interventions
Exendin 9-39
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Role of GLP-1 in Satiety Perception in Humans

NCT01152333
Conditions
Appetite Regulation, Obesity
Interventions
Exendin-(9-39) Acetate, Saline 0.9%
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

NCT01803451
Conditions
Post-bariatric Surgery
Interventions
exendin -(9-39)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

NCT02170870
Conditions
Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions
Exendin 9-39, Microlipid, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), placebo
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772
Conditions
Heart Disease
Interventions
Exendin-9, GLP-1, saline
Drug · Other
Lead sponsor
David Dalessio
Other
Eligibility
40 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio